Kyto BioPharma Inc. announced that they have submitted a Letter of Intent for the acquisition of all outstanding common shares of Barbados Sea Island Cotton Inc (BSC). This will be made through the issuance of 10 million worth of common shares of Kyto BioPharma to the BSC shareholders. BSC used its industry experience, political relationships, and proprietary investments on the Island of Barbados. The company was able to secure all the rights to manage the production. The process will be made through a vertical integration plan that encompasses all the aspects for growing, ginning, knitting, harvesting, spinning, assembling and selling premier "Genuine Certified West Indian Sea Island Cotton" finished products.
The Barbados Sea Island Cotton is tagged as the finest cotton. It represents only one ten-of a thousandth percent of the US$32 billion annual market. BSC plans to increase the production and to market the finest cotton products on a global scale through its own brand to using its existing buyers.
Join the Conversation